{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:13:00Z","timestamp":1777965180769,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.7759\/cureus.108277","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:51:41Z","timestamp":1777963901000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis D in the Middle East: A Review of Disease Burden, Health-System Barriers, and Strategic Directions for Management and Elimination"],"prefix":"10.7759","author":[{"given":"Maryam","family":"Alkhatry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul J","family":"Alwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Alzanbagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fozeya","family":"Alzaabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Al Quraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maen","family":"Al Mattooq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazen","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneera Y","family":"Altarrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawal","family":"Alnahdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeed Husain","family":"Al Marzooqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehia","family":"Nabil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Aba-Alkhail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale AJ","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MY, et al.. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020, 73:523-32. 10.1016\/j.jhep.2020.04.008","journal-title":"J Hepatol"},{"key":"ref2","article-title":"Global Health Sector Strategies On, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022-2030","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Global Health Sector Strategies On, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022-2030. WHO, Geneva; 2022."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.652962","article-title":"Hepatitis delta virus (HDV) and delta-like agents: insights into their origin","volume":"12","author":"Netter HJ","year":"2021","unstructured":"Netter HJ, Barrios MH, Littlejohn M, Yuen LK. Hepatitis delta virus (HDV) and delta-like agents: insights into their origin. Front Microbiol. 2021, 12:652962. 10.3389\/fmicb.2021.652962","journal-title":"Front Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2196\/37016","article-title":"Underestimated prevalence of HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) triple infection globally: systematic review and meta-analysis","volume":"8","author":"Chen S","year":"2022","unstructured":"Chen S, Ren F, Huang X, et al.. Underestimated prevalence of HIV, hepatitis B virus (HBV), and hepatitis D virus (HDV) triple infection globally: systematic review and meta-analysis. JMIR Public Health Surveill. 2022, 8:e37016. 10.2196\/37016","journal-title":"JMIR Public Health Surveill"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15338","article-title":"Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: a scoping review","volume":"43 Suppl 1","author":"Lazarus JV","year":"2023","unstructured":"Lazarus JV, Al-Rifai A, Sanai FM, et al.. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: a scoping review. Liver Int. 2023, 43 Suppl 1:116-23. 10.1111\/liv.15338","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao Z","year":"2020","unstructured":"Miao Z, Zhang S, Ou X, et al.. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020, 221:1677-87. 10.1093\/infdis\/jiz633","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/v13101912","article-title":"Hepatitis D review: challenges for the resource-poor setting","volume":"13","author":"Lee AU","year":"2021","unstructured":"Lee AU, Lee C. Hepatitis D review: challenges for the resource-poor setting. Viruses. 2021, 13:1912. 10.3390\/v13101912","journal-title":"Viruses"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9312650","article-title":"The epidemiology of hepatitis D virus in North Africa: a systematic review and meta-analysis","volume":"2018","author":"Daw MA","year":"2018","unstructured":"Daw MA, Daw AM, Sifennasr NE, et al.. The epidemiology of hepatitis D virus in North Africa: a systematic review and meta-analysis. ScientificWorldJournal. 2018, 2018:9312650. 10.1155\/2018\/9312650","journal-title":"ScientificWorldJournal"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0289-2018","article-title":"Hepatitis delta prevalence in South America: a systematic review and meta-analysis","volume":"52","author":"Scarponi CF","year":"2019","unstructured":"Scarponi CF, Silva RD, Souza Filho JA, Guerra MR, Pedrosa MA, Mol MP. Hepatitis delta prevalence in South America: a systematic review and meta-analysis. Rev Soc Bras Med Trop. 2019, 52:e20180289. 10.1590\/0037-8682-0289-2018","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11901-024-00643-w","article-title":"Advances and challenges in managing hepatitis D virus: evolving strategies","volume":"23","author":"Gopalakrishna H","year":"2024","unstructured":"Gopalakrishna H, Mironova M, Dahari H, Koh C, Heller T. Advances and challenges in managing hepatitis D virus: evolving strategies. Curr Hepatol Rep. 2024, 23:32-44. 10.1007\/s11901-024-00643-w","journal-title":"Curr Hepatol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13050362","article-title":"Hepatitis delta virus and hepatocellular carcinoma","volume":"13","author":"Lombardo D","year":"2024","unstructured":"Lombardo D, Franz\u00e8 MS, Caminiti G, Pollicino T. Hepatitis delta virus and hepatocellular carcinoma. Pathogens. 2024, 13:362. 10.3390\/pathogens13050362","journal-title":"Pathogens"},{"key":"ref12","unstructured":"World Hepatitis Alliance. WHO global hepatitis report 2024. (2024). Accessed. January 30, 2026: https:\/\/www.worldhepatitisalliance.org\/wp-content\/uploads\/2024\/07\/WHA-Global-Hepatitis-Report_FINAL.pdf."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-021-00462-0","article-title":"Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis","volume":"13","author":"Chen LY","year":"2021","unstructured":"Chen LY, Pang XY, Goyal H, Yang RX, Xu HG. Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis. Gut Pathog. 2021, 13:66. 10.1186\/s13099-021-00462-0","journal-title":"Gut Pathog"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen HY","year":"2019","unstructured":"Chen HY, Shen DT, Ji DZ, et al.. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019, 68:512-21. 10.1136\/gutjnl-2018-316601","journal-title":"Gut"},{"key":"ref15","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis. Refugee health domestic guidance. (2025). Accessed. December 9, 2025: https:\/\/www.cdc.gov\/immigrant-refugee-health\/hcp\/domestic-guidance\/viral-hepatitis.html."},{"key":"ref16","unstructured":"Centers for Disease Control and Prevention. Refugee health domestic guidance. (2025). Accessed. n.d: https:\/\/www.cdc.gov\/immigrant-refugee-health\/hcp\/domestic-guidance\/index.html."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13690-021-00693-2","article-title":"The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?","volume":"79","author":"Hayashi T","year":"2021","unstructured":"Hayashi T, Takeshita Y, Hutin YJ, et al.. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. Arch Public Health. 2021, 79:180. 10.1186\/s13690-021-00693-2","journal-title":"Arch Public Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000687","article-title":"Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: an analysis of the All-Payer Claims Database","volume":"79","author":"Gish RG","year":"2024","unstructured":"Gish RG, Jacobson IM, Lim JK, et al.. Prevalence and characteristics of hepatitis delta virus infection in patients with hepatitis B in the United States: an analysis of the All-Payer Claims Database. Hepatology. 2024, 79:1117-28. 10.1097\/HEP.0000000000000687","journal-title":"Hepatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/sjg.SJG_515_16","article-title":"Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: a single-center study","volume":"23","author":"Jamjoom GA","year":"2017","unstructured":"Jamjoom GA, El-Daly MM, Azhar EI, et al.. Prevalence and molecular characterization of hepatitis D virus in Saudi Arabia: a single-center study. Saudi J Gastroenterol. 2017, 23:176-82. 10.4103\/sjg.SJG_515_16","journal-title":"Saudi J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806007643","article-title":"Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon","volume":"135","author":"Ramia S","year":"2007","unstructured":"Ramia S, El-Zaatari M, Sharara AI, Ramlawi F, Farhat B. Current prevalence of hepatitis delta virus (HDV) infection and the range of HDV genotypes in Lebanon. Epidemiol Infect. 2007, 135:959-62. 10.1017\/S0950268806007643","journal-title":"Epidemiol Infect"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2018.12.001","article-title":"Hepatitis D virus infection among hepatitis B virus surface antigen positive individuals in Upper Egypt: prevalence and clinical features","volume":"12","author":"Makhlouf NA","year":"2019","unstructured":"Makhlouf NA, Morsy KH, Mahmoud AA. Hepatitis D virus infection among hepatitis B virus surface antigen positive individuals in Upper Egypt: prevalence and clinical features. J Infect Public Health. 2019, 12:350-6. 10.1016\/j.jiph.2018.12.001","journal-title":"J Infect Public Health"},{"key":"ref22","article-title":"The prevalence of hepatitis D virus infection amongst patients with chronic active hepatitis B virus infection in Duhok Governorate","volume":"28","author":"Hussein N","year":"2015","unstructured":"Hussein N, Rasheed Z, Taha A, Shaikhow S. The prevalence of hepatitis D virus infection amongst patients with chronic active hepatitis B virus infection in Duhok Governorate. J Gastroenterol Hepatol Res. 2015, 28:1-7.","journal-title":"J Gastroenterol Hepatol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3923\/ijv.2015.133.138","article-title":"Sero-molecular epidemiology and risk factors of viral hepatitis in urban Yemen","volume":"11","author":"Nabehi BAH","year":"2015","unstructured":"Nabehi BAH, Al-Shamahy H, Saeed W, et al.. Sero-molecular epidemiology and risk factors of viral hepatitis in urban Yemen. Int J Virol. 2015, 11:133-8. 10.3923\/ijv.2015.133.138","journal-title":"Int J Virol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0000790","article-title":"A changing landscape: tracking and analysis of the international HDV epidemiology 1999-2020","volume":"3","author":"Fallon BS","year":"2023","unstructured":"Fallon BS, Cooke EM, Hesterman MC, Norseth JS, Akhundjanov SB, Weller ML. A changing landscape: tracking and analysis of the international HDV epidemiology 1999-2020. PLOS Glob Public Health. 2023, 3:e0000790. 10.1371\/journal.pgph.0000790","journal-title":"PLOS Glob Public Health"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18745","article-title":"Air pollution tied with increased chance of breast cancer","volume":"330","author":"Harris E","year":"2023","unstructured":"Harris E. Air pollution tied with increased chance of breast cancer. JAMA. 2023, 330:1422. 10.1001\/jama.2023.18745","journal-title":"JAMA"},{"key":"ref26","unstructured":"World Health Organization. WHO urges action on hepatitis, announcing hepatitis D as carcinogenic. (2025). Accessed. December 20, 2025: https:\/\/www.who.int\/news\/item\/28-07-2025-who-urges-action-on-hepatitis-announcing-hepatitis-d-as-carcinogenic."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.01.025","article-title":"Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia","volume":"11","author":"Brichler S","year":"2013","unstructured":"Brichler S, Le Gal F, Butt A, Chevret S, Gordien E. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol. 2013, 11:734-40. 10.1016\/j.cgh.2013.01.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1598784","article-title":"A comprehensive review of diagnostic approaches for hepatitis D","volume":"12","author":"Liu WH","year":"2025","unstructured":"Liu WH, Cui JY, Yu M, Shi XD, Che YL, Wang CY, Chi XM. A comprehensive review of diagnostic approaches for hepatitis D. Front Mol Biosci. 2025, 12:1598784. 10.3389\/fmolb.2025.1598784","journal-title":"Front Mol Biosci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.12.006","article-title":"Unmet need in screening for hepatitis D virus: time to take action","volume":"80","author":"Lai JC","year":"2024","unstructured":"Lai JC, Wong GL, Wong VW, Yip TC. Unmet need in screening for hepatitis D virus: time to take action. J Hepatol. 2024, 80:e277-8. 10.1016\/j.jhep.2023.12.006","journal-title":"J Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67:1560-99. 10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2025.263","article-title":"Progress and challenges in the global elimination of viral hepatitis D","volume":"7","author":"Li M","year":"2025","unstructured":"Li M, Wang Q, Cao W, Xie Y. Progress and challenges in the global elimination of viral hepatitis D. China CDC Wkly. 2025, 7:1549-52. 10.46234\/ccdcw2025.263","journal-title":"China CDC Wkly"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091509","article-title":"Hepatitis management in Saudi Arabia: trends, prevention, and key interventions (2016-2025)","volume":"61","author":"Ryani MA","year":"2025","unstructured":"Ryani MA. Hepatitis management in Saudi Arabia: trends, prevention, and key interventions (2016-2025). Medicina (Kaunas). 2025, 61:1509. 10.3390\/medicina61091509","journal-title":"Medicina (Kaunas)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1005646","article-title":"Prevalence and impact of HBV and HDV infection globally and in MENA region","author":"Makhlouf NA","year":"2024","unstructured":"Makhlouf NA. Prevalence and impact of HBV and HDV infection globally and in MENA region. Hepatitis B Virus - Pathogenesis and Therapeutic Approaches. IntechOpen, London, UK; 2024. 10.5772\/intechopen.1005646"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.02.041","article-title":"Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV\/HDV-prevalence countries","volume":"79","author":"Razavi HA","year":"2023","unstructured":"Razavi HA, Buti M, Terrault NA, et al.. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV\/HDV-prevalence countries. J Hepatol. 2023, 79:576-80. 10.1016\/j.jhep.2023.02.041","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.53854\/liim-3002-5","article-title":"Recent breakthroughs in the treatment of chronic hepatitis Delta","volume":"30","author":"Brancaccio G","year":"2022","unstructured":"Brancaccio G, Gaeta L, Vitale A, Gaeta GB. Recent breakthroughs in the treatment of chronic hepatitis Delta. Infez Med. 2022, 30:204-10. 10.53854\/liim-3002-5","journal-title":"Infez Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3390\/v17081100","article-title":"Updates on recent advancements in hepatitis D virus treatment","volume":"17","author":"Bardak AE","year":"2025","unstructured":"Bardak AE, Ozturk NB, Gurakar M, et al.. Updates on recent advancements in hepatitis D virus treatment. Viruses. 2025, 17:1100. 10.3390\/v17081100","journal-title":"Viruses"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer H","year":"2024","unstructured":"Wedemeyer H, Aleman S, Brunetto M, et al.. Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial. J Hepatol. 2024, 81:621-9. 10.1016\/j.jhep.2024.05.001","journal-title":"J Hepatol"},{"key":"ref38","unstructured":"Lonafarnib with ritonavir slows HDV in 48-week placebo trial. EASL Congress. (2023). Accessed. n.d: https:\/\/www.natap.org\/2023\/EASL\/EASL_78.htm."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01416-17","article-title":"Nucleic acid polymers are active against hepatitis delta virus infection in vitro","volume":"92","author":"Beilstein F","year":"2018","unstructured":"Beilstein F, Blanchet M, Vaillant A, Sureau C. Nucleic acid polymers are active against hepatitis delta virus infection in vitro. J Virol. 2018, 92:10.1128\/JVI.01416-17","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/v14020268","article-title":"Combination of novel therapies for HDV","volume":"14","author":"Elazar M","year":"2022","unstructured":"Elazar M, Glenn JS. Combination of novel therapies for HDV. Viruses. 2022, 14:268. 10.3390\/v14020268","journal-title":"Viruses"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327216","article-title":"Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections","volume":"72","author":"Burm R","year":"2023","unstructured":"Burm R, Maravelia P, Ahlen G, et al.. Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections. Gut. 2023, 72:1186-95. 10.1136\/gutjnl-2022-327216","journal-title":"Gut"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer H","year":"2023","unstructured":"Wedemeyer H, Aleman S, Brunetto MR, et al.. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023, 389:22-32. 10.1056\/NEJMoa2213429","journal-title":"N Engl J Med"},{"key":"ref43","unstructured":"Week 48 results of the phase 3 D-LIVR study, a randomized double-blind, placebo-controlled trial evaluating the safety and efficacy of lonafarnib boosted with ritonavir with or without peginterferon alfa in patients with chronic hepatitis delta. International Liver Congress, EASL. (2023). Accessed. n.d: https:\/\/www.natap.org\/2023\/EASL\/EASL_34.htm."},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64122-0","article-title":"Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg","volume":"10","author":"Shekhtman L","year":"2020","unstructured":"Shekhtman L, Cotler SJ, Hershkovich L, et al.. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Sci Rep. 2020, 10:7837. 10.1038\/s41598-020-64122-0","journal-title":"Sci Rep"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah T","year":"2024","unstructured":"Asselah T, Chulanov V, Lampertico P, et al.. Bulevirtide combined with pegylated interferon for chronic hepatitis D. N Engl J Med. 2024, 391:133-43. 10.1056\/NEJMoa2314134","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion O","year":"2023","unstructured":"Etzion O, Hamid S, Lurie Y, et al.. Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial. Hepatology. 2023, 77:2093-103. 10.1097\/HEP.0000000000000309","journal-title":"Hepatology"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508827","article-title":"A phase 2 trial of tobevibart plus elebsiran in hepatitis D","volume":"394","author":"Asselah T","year":"2026","unstructured":"Asselah T, Chattergoon MA, Jucov A, et al.. A phase 2 trial of tobevibart plus elebsiran in hepatitis D. N Engl J Med. 2026, 394:343-53. 10.1056\/NEJMoa2508827","journal-title":"N Engl J Med"},{"key":"ref48","unstructured":"Hepatitis D market - a global and regional analysis. (2024). Accessed. January 14, 2026: https:\/\/bisresearch.com\/industry-report\/hepatitis-d-market.html."},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.5888\/pcd17.200324","article-title":"Needs of individuals living with hepatitis delta virus and their caregivers, 2016-2019","volume":"17","author":"Kumar P","year":"2020","unstructured":"Kumar P, Freeland C, Bodor S, Farrell S, Cohen C, Frasso R. Needs of individuals living with hepatitis delta virus and their caregivers, 2016-2019. Prev Chronic Dis. 2020, 17:E159. 10.5888\/pcd17.200324","journal-title":"Prev Chronic Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.26719\/2016.22.4.267","article-title":"Hepatitis B and C in the Syrian Arab Republic: a review","volume":"22","author":"Bashour H","year":"2016","unstructured":"Bashour H, Muhjazi G. Hepatitis B and C in the Syrian Arab Republic: a review. East Mediterr Health J. 2016, 22:267-73. 10.26719\/2016.22.4.267","journal-title":"East Mediterr Health J"},{"key":"ref51","unstructured":"Health insurance in the Middle East. coverage, challenges, and accessibility. (2025). Accessed: Dec 20, 2025: https:\/\/shunins.com\/article\/do-middle-eastern-countries-have-health-insurance."},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13779","article-title":"The Delta Delta: gaps in screening and patient assessment for hepatitis D virus infection","volume":"30","author":"Nathani R","year":"2023","unstructured":"Nathani R, Leibowitz R, Giri D, et al.. The Delta Delta: gaps in screening and patient assessment for hepatitis D virus infection. J Viral Hepat. 2023, 30:195-200. 10.1111\/jvh.13779","journal-title":"J Viral Hepat"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","author":"Brunetto MR","year":"2023","unstructured":"Brunetto MR, Ricco G, Negro F, et al.. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023, 79:433-60. 10.1016\/j.jhep.2023.05.001","journal-title":"J Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin SK","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al.. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016, 10:1-98. 10.1007\/s12072-015-9675-4","journal-title":"Hepatol Int"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1422299","article-title":"Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring","volume":"14","author":"Illescas-L\u00f3pez M","year":"2024","unstructured":"Illescas-L\u00f3pez M, Chaves-Blanco L, de Salazar A, et al.. Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring. Front Cell Infect Microbiol. 2024, 14:1422299. 10.3389\/fcimb.2024.1422299","journal-title":"Front Cell Infect Microbiol"},{"key":"ref56","unstructured":"World Health Organization. Elimination of hepatitis by 2030. (2026). Accessed. January 30, 2026: https:\/\/www.who.int\/health-topics\/hepatitis\/elimination-of-hepatitis-by-2030."},{"key":"ref57","unstructured":"World Health Organization. Global hepatitis report 2024. action for access in low- and middle-income countries. (2024). Accessed: Dec 20, 2025: https:\/\/www.who.int\/publications\/i\/item\/9789240091672."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482590-hepatitis-d-in-the-middle-east-a-review-of-disease-burden-health-system-barriers-and-strategic-directions-for-management-and-elimination","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:51:44Z","timestamp":1777963904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482590-hepatitis-d-in-the-middle-east-a-review-of-disease-burden-health-system-barriers-and-strategic-directions-for-management-and-elimination"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.108277","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,4]]}}}